Prognostic Significance of Peripheral Artery Disease in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

被引:0
|
作者
Xia, Yihua [1 ]
Han, Kangning [2 ]
Cheng, Yujing [1 ]
Wang, Zhijian [1 ]
Gao, Fei [1 ]
Ma, Xiaoteng [1 ]
Zhou, Yujie [1 ]
机构
[1] Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
peripheral artery disease; acute coronary syndrome; percutaneous coronary intervention; cardiovascular outcomes; VASCULAR-DISEASE; GLOBAL REGISTRY; MORTALITY; RISK; EVENTS; OUTCOMES;
D O I
10.31083/j.rcm2411332
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Peripheral artery disease (PAD) elevates the risk of adverse outcomes. The current work aimed to evaluate the influence of PAD in acute coronary syndrome (ACS) cases administered percutaneous coronary intervention (PCI), and to determine whether PAD adds incremental prognostic value to the global registry of acute coronary events (GRACE) scale. Methods: To retrospectively analyze a single-center, prospective cohort trial, we consecutively included ACS cases administered PCI. Individuals with and without PAD were comparatively examined for clinical outcomes. The primary endpoint was major adverse cardiovascular events (MACEs), a compound item encompassing all-cause death, myocardial infarction (MI), stroke and repeat revascularization. The added value of PAD based on a reference model was examined. Results: PAD was detected in 179 (10.4%) of the 1,770 included patients. The incidence rates of MACEs (40.3% vs. 17.9%), all-cause death (11.2% vs. 1.6%), cardiovascular death (8.9% vs. 1.4%), MI (8.4% vs. 2.2%) and repeat revascularization (30.2% vs. 15.2%) were all markedly elevated in PAD cases in comparison with the non-PAD group (p < 0.001). After adjusting for other confounding variates, PAD independently predicted MACE occurrence (hazard ratio =1.735, 95% confidence interval: 1.281-2.351). Addition of PAD resulted in remarkably increased predictive performance for MACE compared to the baseline GRACE score (Harrell's C-statistic: 0.610 vs. 0.587, p < 0.001; net reclassification improvement: 0.134, p < 0.001; integrated discrimination improvement: 0.035, p < 0.001). Conclusions: In ACS cases administered PCI, PAD independently worsens clinical outcomes and adds incremental value to the GRACE risk score.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention
    Momiyama, Yukihiko
    Tanaka, Nobukiyo
    Ohmori, Reiko
    Kato, Ryuichi
    Taniguchi, Hiroaki
    Arakawa, Koh
    Nakamura, Haruo
    Ohsuzu, Fumitaka
    CIRCULATION, 2007, 116 (16) : 850 - 850
  • [42] Prognostic Significance of Plasma Osteopontin Levels in Patients Undergoing Percutaneous Coronary Intervention
    Kato, Ryuichi
    Momiyama, Yukihiko
    Ohmori, Reiko
    Tanaka, Nobukiyo
    Taniguchi, Hiroaki
    Arakawa, Koh
    Nakamura, Haruo
    Ohsuzu, Fumitaka
    CIRCULATION JOURNAL, 2009, 73 (01) : 152 - 157
  • [43] Prognostic significance of plasma soluble thrombomodulin in patients undergoing percutaneous coronary intervention
    Chao, TH
    Li, YH
    Chen, JH
    Tsai, WC
    EUROPEAN HEART JOURNAL, 2001, 22 : 27 - 27
  • [44] PROGNOSTIC SIGNIFICANCE OF SERUM RESISTIN LEVELS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    Momiyama, Yukihiko
    Ohmori, Reiko
    Kato, Ryuichi
    Taniguchi, Hiroaki
    Nakamura, Haruo
    Ohsuzu, Fumitaka
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [45] Prognostic significance of Troponin I in patients undergoing primary percutaneous coronary intervention
    Sane, Pratik Sudhir
    Manoj, V
    Demel, Rufus
    Vijaykumar, S.
    Mullasari, Ajit S.
    INDIAN HEART JOURNAL, 2021, 73 (06) : 737 - 739
  • [46] PROGNOSTIC SIGNIFICANCE OF MYOCARDIAL BRIDGE IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
    Setoguchi, Mirei
    Usui, Eisuke
    Hada, Masahiro
    Nagamine, Tatsuhiro
    Ueno, Hiroki
    Nogami, Kai
    Tahara, Tomohiro
    Mineo, Takashi
    Yonetsu, Taishi
    Kakuta, Tsunekazu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1012 - 1012
  • [47] Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
    Norgard, Nicholas B.
    Abu-Fadel, Mazen
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 873 - 882
  • [48] Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
    Fioretti, Vincenzo
    Sperandeo, Luca
    Gerardi, Donato
    Di Fazio, Aldo
    Stabile, Eugenio
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
  • [49] Safety and Effectiveness of Rivaroxaban in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention
    Li Xiaoyan
    Lu Ying
    Zhang Er Hong
    Zhang Ping
    Zhang Ping
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C150 - C150
  • [50] Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention
    Coughlan, J. J.
    Aytekin, Alp
    Ndrepepa, Gjin
    Schuepke, Stefanie
    Bernlochner, Isabell
    Mayer, Katharina
    Neumann, Franz Josef
    Menichelli, Maurizio
    Richardt, Gert
    Woehrle, Jochen
    Witzenbichler, Bernhard
    Gewalt, Senta
    Xhepa, Erion
    Kufner, Sebastian
    Sager, Hendrik B.
    Joner, Michael
    Ibrahim, Tareq
    Fusaro, Massimiliano
    Laugwitz, Karl Ludwig
    Schunkert, Heribert
    Kastrati, Adnan
    Cassese, Salvatore
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (07) : E010565